https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00222-3/fulltext
We read the Comment by Amit Saxena and colleagues1 regarding the clinical efficacy and seroreactivity of an additional COVID-19 vaccine dose in patients with systemic lupus erythematosus with great interest.1 Samples were analysed at a mean of 44·7 days (SD 3…
Create an account or login to join the discussion